Christopher James Frankenfield Xilio Therapeutics, Inc. (XLO) insider trading activity

XLO Quotes by TradingView

Christopher James Frankenfield is Chief Financial Officer of Xilio Therapeutics, Inc.. Currently has a direct ownership of 24,766 shares of XLO, which is worth approximately $17,336. The most recent transaction as insider was on Jan 02, 2026, when has been sold 7,030 shares (Common Stock) at a price of $0.64 per share, resulting in proceeds of $4,499. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 24.8K
99.39% 3M change
99.39% 12M change
Total Value Held $17,336

Christopher James Frankenfield Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 02 2026
SELL
Open market or private sale
$4,499 $0.64 p/Share
7,030 Reduced 22.11%
24,766 Common Stock
Jan 01 2026
BUY
Exercise of conversion of derivative security
-
19,375 Added 37.86%
31,796 Common Stock
Jan 02 2025
SELL
Open market or private sale
$6,814 $0.98 p/Share
6,954 Reduced 35.89%
12,421 Common Stock
Jan 01 2025
BUY
Exercise of conversion of derivative security
-
19,375 Added 50.0%
19,375 Common Stock
CJF

Christopher James Frankenfield

Chief Financial Officer
Waltham, MA

Track Institutional and Insider Activities on XLO

Follow Xilio Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells XLO shares.

Notify only if

Insider Trading

Get notified when an Xilio Therapeutics, Inc. insider buys or sells XLO shares.

Notify only if

News

Receive news related to Xilio Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on XLO